RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+6.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$251M
AUM Growth
–
Cap. Flow
+$251M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
29.9%
Holding
83
New
83
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$10.2M |
| 2 |
CELG
Celgene Corp
CELG
|
$8.28M |
| 3 |
Gilead Sciences
GILD
|
$8.19M |
| 4 |
CVS Health
CVS
|
$7.66M |
| 5 |
Biogen
BIIB
|
$7.55M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 84.16% |
| 2 | Financials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nektar Therapeutics
NKTR
$543M
| $2.16M | 0.84% |
+12,667
| New | +$2.16M |
|
52
Integra LifeSciences
IART
$1.18B
| $2.15M | 0.84% |
+110,091
| New | +$2.15M |
|
53
Exelixis
EXEL
$9.95B
| $2.15M | 0.84% |
+350,000
| New | +$2.15M |
|
54
Acadia Pharmaceuticals
ACAD
$4.34B
| $2.12M | 0.83% |
+85,000
| New | +$2.12M |
|
55
McKesson
MCK
$85.9B
| $2.1M | 0.82% |
+13,000
| New | +$2.1M |
|
56
Centene
CNC
$14.8B
| $2.06M | 0.81% |
+140,000
| New | +$2.06M |
|
57
Ligand Pharmaceuticals
LGND
$3.25B
| $2M | 0.78% |
+60,914
| New | +$2M |
|
58
Revvity
RVTY
$9.68B
| $1.86M | 0.73% |
+45,000
| New | +$1.86M |
|
|
ARRY
59
DELISTED
Array Biopharma Inc
ARRY
| $1.8M | 0.71% |
+360,000
| New | +$1.8M |
|
60
Eli Lilly
LLY
$661B
| $1.79M | 0.7% |
+35,000
| New | +$1.79M |
|
61
Community Health Systems
CYH
$392M
| $1.77M | 0.69% |
+54,450
| New | +$1.77M |
|
|
AUXL
62
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $1.76M | 0.69% |
+85,000
| New | +$1.76M |
|
|
BCR
63
DELISTED
CR Bard Inc.
BCR
| $1.74M | 0.68% |
+13,000
| New | +$1.74M |
|
|
ABMD
64
DELISTED
Abiomed Inc
ABMD
| $1.74M | 0.68% |
+65,000
| New | +$1.74M |
|
65
Supernus Pharmaceuticals
SUPN
$2.52B
| $1.7M | 0.66% |
+225,000
| New | +$1.7M |
|
66
Myriad Genetics
MYGN
$633M
| $1.69M | 0.66% |
+80,759
| New | +$1.69M |
|
|
AGN
67
DELISTED
Allergan plc
AGN
| $1.68M | 0.66% |
+10,000
| New | +$1.68M |
|
68
Hologic
HOLX
$14.7B
| $1.61M | 0.63% |
+72,000
| New | +$1.61M |
|
|
IMGN
69
DELISTED
Immunogen Inc
IMGN
| $1.47M | 0.57% |
+100,000
| New | +$1.47M |
|
|
ELGX
70
DELISTED
Endologix Inc
ELGX
| $1.41M | 0.55% |
+8,103
| New | +$1.41M |
|
|
OREX
71
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $1.41M | 0.55% |
+25,000
| New | +$1.41M |
|
|
CPHD
72
DELISTED
Cepheid Inc
CPHD
| $1.4M | 0.55% |
+30,000
| New | +$1.4M |
|
73
Haemonetics
HAE
$2.57B
| $1.26M | 0.49% |
+30,000
| New | +$1.26M |
|
|
MTEM
74
DELISTED
Molecular Templates, Inc.
MTEM
| $1.17M | 0.46% |
+1,515
| New | +$1.17M |
|
75
Cardiff Oncology
CRDF
$130M
| $1.15M | 0.45% |
+2,778
| New | +$1.15M |
|